Pacira Biosciences (PCRX) Stock Price
Pacira Biosciences Price
Revenue has compounded at 23.9% per year over the past 19 years to 726.41 M USD. Earnings per share have grown at 12.5% per year over the last 10 years. Pacira Biosciences's net margin stands at 1.0%, down from 7.8% several years earlier. Analysts set a median price target of 30.00 USD, implying 17.7% below the current price. Of 14 analysts, 0 rate the stock a buy — an overall Hold consensus.
Pacira Biosciences stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Pacira Biosciences business model & stock analysis
Frequently asked questions about Pacira Biosciences
The business model of Pacira Biosciences Inc is focused on developing and commercializing innovative pharmaceutical products for use in hospitals and ambulatory surgery centers. The company specializes in creating and delivering non-opioid pain management therapies. Pacira Biosciences Inc's flagship product, EXPAREL®, is a long-acting local analgesic that provides extended pain relief after surgery. With a strong emphasis on research and development, Pacira Biosciences Inc aims to improve patient outcomes and reduce opioid consumption by providing alternative pain management solutions. This commitment to innovation and patient care drives the company's success in the healthcare industry.
Pacira Biosciences Inc primarily operates in the pharmaceutical industry.
The main competitors of Pacira Biosciences Inc in the market include Johnson & Johnson, Pfizer Inc, and Teva Pharmaceutical Industries Ltd. These companies operate in the pharmaceutical industry and offer similar products and services. Pacira Biosciences Inc faces competition in its primary focus area of developing and commercializing innovative pharmaceutical products for post-surgical pain management. Competitors like Johnson & Johnson, Pfizer Inc, and Teva Pharmaceutical Industries Ltd constantly strive to capture market share by introducing new products and technologies. However, Pacira Biosciences Inc has successfully positioned itself as a competitive player in the market through its strong product portfolio and focus on research and development efforts.
Pacira Biosciences Inc is a leading pharmaceutical company specializing in non-opioid pain management and regenerative health solutions. Established in 2006, the company is headquartered in Parsippany, New Jersey. Pacira Biosciences focuses on developing innovative therapies for acute pain management and surgical applications. With a dedication to improving patient outcomes and reducing opioid dependence, they have introduced groundbreaking products like EXPAREL®, a long-acting local analgesic. Pacira Biosciences has transformed pain management practices across various surgical specialties, providing patients with effective alternatives to opioids. The company's commitment to research, development, and pioneering advancements makes Pacira Biosciences Inc a trusted name in the healthcare industry.
Pacira Biosciences Inc, a renowned pharmaceutical company, has achieved several significant milestones. Notably, the company successfully developed and commercialized Exparel, a cutting-edge non-opioid pain management medication widely used in surgical procedures. Pacira Biosciences Inc also made significant progress in expanding its product pipeline by successfully launching iovera, a minimally invasive treatment option for managing pain. Additionally, the company's continuous commitment to research and development has led to numerous innovative drug formulations and collaborations with global healthcare institutions. Through its steadfast dedication to improving patient outcomes, Pacira Biosciences Inc has cemented its position as a leading player in the pharmaceutical industry.
Pacira Biosciences Inc is primarily present in various countries and regions worldwide. The company has established its presence in the United States, enabling it to cater to the North American market effectively. Additionally, Pacira Biosciences Inc has expanded its reach globally, with a strong presence in Europe, Asia, and other international regions. By strategically establishing its presence in multiple countries and regions, Pacira Biosciences Inc aims to provide its innovative healthcare solutions and products to a diverse range of patients and healthcare providers across the globe.
Pacira Biosciences Inc represents a commitment to improving patient outcomes and transforming the surgical experience. Their corporate philosophy is centered around finding innovative solutions for postsurgical pain management and reducing opioid use. With a focus on responsible drug development, Pacira prioritizes patient safety, clinical evidence, and collaboration with healthcare professionals. The company strives to provide patients with non-opioid alternatives for pain control, aiming to enhance recovery and minimize the risk of opioid-related complications. Pacira Biosciences Inc emphasizes ethical practices and dedicated research to address unmet medical needs in surgical care.
Analysts currently set an average price target of 29.00 USD for the Pacira Biosciences stock (median: 30.00 USD), implying -20.5 % versus the latest price. The consensus is based on 14 analyst ratings.
14 analysts currently rate the Pacira Biosciences stock: 0 recommend buying, 11 holding and 3 selling. For 2026, analysts expect Pacira Biosciences to generate revenue of 754.33 M USD and earnings per share of 3.03 USD.
Converted at the current exchange rate, the Pacira Biosciences share trades at 32.81 EUR (36.46 USD).
The Pacira Biosciences share (PCRX) is listed on 5 stock exchanges, including: NASDAQ (PCRX), SIX (Zürich) (82P.SW), Frankfurt (82P.F), München (82P.MU), Düsseldorf (82P.DU).
Pacira Biosciences Inc is a global pharmaceutical company specializing in the development, manufacturing, and marketing of innovative pain relief medications. The company was founded in 1999 and is headquartered in Parsippany, New Jersey, USA. It is listed on the NASDAQ stock exchange and employs over 1,300 people worldwide. The company's business model is based on the research and development of medications focused on pain treatment. Pacira Biosciences focuses on developing medications using its proprietary liposome technology, which helps to effectively and prolong the action of active substances in the body, thereby improving pain relief. Pacira Biosciences Inc's products mainly include Exparel (Bupivacaine liposome injectable suspension), a long-acting pain medication used for postoperative pain management. Exparel is used in orthopedics, gynecology, plastic surgery, general surgery, and other areas where pain relief is needed during the recovery phase after surgery. In addition to Exparel, Pacira Biosciences also has a pipeline of development projects for new medications, including DepoCyt (Cytarabine liposome injection), a medication for certain types of cancer. The company is divided into three business segments: Products, Research and Development, and Corporate. The Products segment is responsible for marketing and sales of Exparel in the US and Europe. The Research and Development segment is responsible for the development of new medications and pain therapy technologies. The Corporate segment coordinates general operational matters, finances, human resources, legal and compliance issues, as well as marketing and communication activities for the company. Overall, Pacira Biosciences Inc's business model focuses on developing and marketing innovative and effective pain medications based on its liposome technology. It primarily addresses the needs of patients and doctors for improved pain relief in postoperative pain management.
The expected revenue of Pacira Biosciences is 754.33 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Pacira Biosciences is 130.44 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Pacira Biosciences is currently 12.01. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Pacira Biosciences stock.
The price-to-sales ratio (P/S) of Pacira Biosciences is currently 2.08. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Pacira Biosciences stock.
The Eulerpool Quality Score for Pacira Biosciences is 3/10.
The ISIN of Pacira Biosciences is US6951271005. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Pacira Biosciences is A1H68T. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Pacira Biosciences is PCRX. The ticker symbol is used to trade Pacira Biosciences shares on the stock exchange.
Pacira Biosciences stock
Pacira Biosciences Peer Group
Pacira Biosciences Ticker
Pacira Biosciences FIGI
All fundamentals and in-depth analysis of Pacira Biosciences
Our stock analysis for Pacira Biosciences stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pacira Biosciences. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.